Arno Therapeutics Selects Leica Biosystems To Develop Companion Diagnostic For Targeted Oncology Therapy Onapristone
1/7/2014 9:36:53 AM
FLEMINGTON, N.J. and NEWCASTLE UPON TYNE, England, Jan. 7, 2014 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI); (Arno), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, and Leica Biosystems (LBS), a global leader in pathology workflow solutions and automation, announced that the companies have entered into a co-development agreement for the development of a companion diagnostic (CDx) for Arno's lead compound and personalized therapy, onapristone.
Help employers find you! Check out all the jobs and post your resume.
comments powered by